The CHIP-LMO7-BAG5 complex controls tau clearance and yields repurposed and newly designed therapeutic candidates for Alzheimer's disease
Kim, J.-Y.; Tadros, B.; Vaidya, B.; Liang, Y. H.; Jung, S. Y.; Deng, X.; Xu, J.; Zoghbi, H. Y.
Show abstract
Through cross-species genetic screens, we identified LMO7 as a regulator of tau levels in vivo. LMO7 bridges the E3 ligase CHIP and its inhibitory cochaperone BAG5, suppressing CHIPs ligase activity and limiting tau ubiquitination and degradation. Adult LMO7 knockdown enhances CHIP activity, reduces total and phosphorylated tau, attenuates gliosis, and rescues memory deficits in tauopathy mice. Guided by AlphaFold-derived structural models and AI-based virtual screening, we developed a CHIP-derived competing peptide and identified FDA-approved drugs that disrupt the complex. Viral delivery of the peptide or oral administration of Telmisartan or MPA-2, an optimized Mycophenolic acid derivative, reduced pathogenic tau without toxicity. These findings establish CHIP-LMO7-BAG5 complex as a druggable node in tau homeostasis, with implications for tauopathies including Alzheimers disease, and STUB1-associated ataxias.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- Neurons burdened by DNA double strand breaks incite microglia activation through antiviral-like signaling in neurodegeneration. 95%
- Astrocytic TDP-43 dysregulation impairs memory by modulating antiviral pathways and interferon-inducible chemokines 94%
- Tau pathology spreads between anatomically-connected regions of the brain and is modulated by a LRRK2 mutation 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.